Key Takeaways:
5-Year Pilot Program: Starting as early as 2026, Medicaid and Medicare may opt to cover GLP-1 weight-loss drugs like Ozempic and Wegovy, expanding access beyond diabetes-related conditions.
Big Costs, Big Market: The drugs run up to $7,000 per year, with analysts...
